pharma · Influenza · Encephalitis, Japanese B
Repatha
Repatha is a pharma organization headquartered in JP. Primary therapeutic focus areas include Influenza, Encephalitis, Japanese B, Malaria, Vivax. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 pate
JP HQ
PMDA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Programs
- 3
- Drugs
- 6
- Patents
- 0
Live attenuated SA 14-14-2 vaccine
Phase 3 · mab · Encephalitis, Japanese B
Live attenuated SA 14-14-2 vaccine for Encephalitis, Japanese B is a Phase 3 program (mab) at Repatha with 1 ClinicalTrials.gov record(s).
Internal code JEV02
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Repatha
- Phase
- Phase 3
- Modality
- mab
- Indication
- Encephalitis, Japanese B
- Status
- completed
- Trials
- 1